GlassScriptPhysician profile
Matthew A Shlapack
NPI 1982729109
$2,410.02
in general payments reported to CMS, 2019-2025
26 companies · $391 in 2025
The $391 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $310 · 2021: $123 · 2022: $396 · 2023: $510 · 2024: $255 · 2025: $391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,156.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $349.86 | 2019-2025 | Synthroid |
| Amgen INC. | $345.27 | 2019-2025 | Evenity, Prolia, Tepezza |
| Novo Nordisk INC | $320.50 | 2019-2025 | Ozempic, Rybelsus, Sogroya |
| Medtronic, INC. | $300.97 | 2022-2025 | Minimed 780g, Minimed 770g |
| Abbott Laboratories | $258.76 | 2019-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $140.06 | 2019 | |
| Dexcom, INC. | $94.62 | 2019-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $74.35 | 2021-2022 | |
| Radius Health, INC. | $73.69 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $67.01 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $58.09 | 2020-2022 | |
| Tandem Diabetes Care, INC. | $42.13 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $37.35 | 2020-2021 | |
| Corcept Therapeutics | $30.60 | 2021 | |
| Amneal Pharmaceuticals LLC | $25.39 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $24.87 | 2025 | Licart, Tirosint, Flector |
| Averitas Pharma INC. | $24.38 | 2024 | Qutenza |
| Recordati_rare_diseases_inc. | $21.54 | 2025 | Isturisa |
| Merck Sharp & Dohme LLC | $20.93 | 2020 | |
| Becton, Dickinson and Company | $17.90 | 2019 | |
| Kyowa Kirin, INC. | $16.49 | 2024 | Crysvita |
| Janssen Pharmaceuticals, INC | $14.82 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.82 | 2025 | |
| Medtronic Minimed, INC. | $13.37 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.05 | 2019 | |
| Acerus Pharmaceuticals Corporation | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Shlapack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.